A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
Latest Information Update: 19 Apr 2024
Price :
$35 *
At a glance
- Drugs Rigosertib (Primary) ; Rigosertib (Primary)
- Indications Epidermolysis bullosa dystrophica; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 12 Oct 2023 Results presented in an Onconova Therapeutics media release.
- 12 Oct 2023 According to an Onconova Therapeutics media release, data from this study will be presented today in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV).